
https://www.science.org/content/blog-post/sort-training
# What Sort of Training?
16 Nov 2005

## 1. SUMMARY
This article addresses an undergraduate chemistry major's question about whether organic synthesis is still the optimal graduate training path for entering drug discovery. The author strongly advocates for traditional organic synthesis training over academic medicinal chemistry programs, arguing that med-chem graduate programs often produce "fair-to-middling" practitioners who lack deep expertise in any single area—a liability since nobody wants to hire a mediocre generalist when specialists are needed.

The core argument is that medicinal chemistry departments in industry specifically need organic chemists with deep synthetic expertise because they're the only ones who truly understand synthesis at an expert level. Total synthesis, despite being a "slowly dying art form," still provides the ideal training because it forces students to master diverse synthetic techniques, develop broad problem-solving skills, and learn to find alternative synthetic routes—skills directly transferable to medicinal chemistry even though industry rarely uses 32-step sequences. The author expresses concern that as total synthesis becomes less common, the pipeline of properly trained chemists for drug discovery may dry up, while acknowledging that new synthetic methods research can also be valuable training if it provides broad experience rather than narrow specialization.

## 2. HISTORY
In the two decades since this article's publication, the pharmaceutical and biotechnology landscape has evolved in ways that both validate and challenge the author's perspective. Drug discovery has indeed shifted toward more targeted, mechanism-based approaches with increased reliance on biologics, computational methods, and platform technologies.

**Changes in Drug Discovery Approaches:**
- The monoclonal antibody and protein therapeutic markets have grown dramatically since 2005, with biologics now representing a substantial portion of drug development pipelines and approved drugs. This has created demand for expertise in protein engineering, antibody discovery, and biologics manufacturing rather than purely small-molecule synthesis.
- Structure-based drug design, enabled by advances in X-ray crystallography and cryo-EM, has become standard practice, reducing some of the "trial and error" synthesis that characterized earlier discovery efforts.
- DNA-encoded libraries, fragment-based drug discovery, and computational chemistry tools have changed the hit-identification landscape, though synthesis remains crucial for optimization.

**Career Path Evolution:**
- While many medicinal chemists still come from traditional synthetic organic chemistry backgrounds, the field has diversified to include more medicinal chemists, chemical biologists, and computational chemists.
- The rise of biotech startups and platform companies has created alternative career paths that value diverse skill sets over pure synthetic expertise.
- Academic medicinal chemistry programs have evolved, with many now maintaining rigor while providing broader exposure to drug discovery.

**Industrial Impact:**
- Major pharma companies continue hiring synthetic organic chemists, but job descriptions increasingly emphasize multi-disciplinary skills including computational chemistry, data analysis, and biological knowledge.
- Total synthesis groups have indeed declined in some universities, but synthetic methodology and complexity-building studies continue providing valuable training.
- The biotech boom has created high demand for scientists who can work across traditional disciplinary boundaries.

## 3. PREDICTIONS

**Prediction 1 - Total synthesis as a "slowly dying art form"**
- **Outcome: Mixed accuracy.** Academic natural product total synthesis has indeed become less prominent in many chemistry departments, with faculty hiring often favoring chemical biology, methodology, catalysis, or materials chemistry. However, complex molecule synthesis remains vital in pharmaceutical development, and natural product total synthesis continues in specialized centers. The prediction captures a real trend but may overstate the "dying" aspect—it's more a shift in emphasis than disappearance.

**Prediction 2 - Need for organic synthesis expertise in drug industry will remain critical**
- **Outcome: Largely accurate.** Small-molecule drug discovery still heavily relies on synthetic organic chemistry expertise. However, the landscape has diversified with biologics, oligonucleotide therapeutics, and other modalities reducing the exclusive focus on small molecules. The underlying principle—that deep technical expertise matters—has held true, but the specific expertise in demand has broadened.

**Prediction 3 - Medicinal chemistry academic programs will produce inadequate training**
- **Outcome: Partially accurate with evolution.** Many academic medicinal chemistry programs have evolved to provide rigorous training that balances synthetic chemistry with drug discovery knowledge. Industry hiring has adapted to value both traditional synthetic training and more drug-focused training. The author's concern about "fair-to-middling" generalists was valid for some programs, but the field has largely adapted to provide proper training depth.

## 4. INTEREST
Rating: **6/10**

This article captures an important transitional moment in chemistry education and its relationship to industry needs, offering practical career advice grounded in real-world hiring considerations. While focused on a specific niche, it touches on broader themes of disciplinary expertise versus interdisciplinary training that remain relevant in STEM education and industry workforce development today.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20051116-sort-training.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_